Bluebird bio Inc (BLUE)

Currency in USD
4.9700
0.0000(0.00%)
Closed·
Showing Bluebird historical data. For real-time data please try another search
Fair Value
Day's Range
4.67005.0300
52 wk Range
3.20005.4200
Key Statistics
Prev. Close
4.97
Open
4.74
Day's Range
4.67-5.03
52 wk Range
3.2-5.42
Volume
-
Average Volume (3m)
581.4K
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BLUE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Currently not supported.
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Bluebird bio Inc News & Analysis

Show more

Bluebird bio Inc SWOT Analysis


Financial Tightrope
luebird bio faces critical cash constraints, with resources projected to last only until Q2 2025, raising concerns about long-term viability and product launch execution
Gene Therapy Promise
Explore bluebird's innovative treatments for genetic diseases, including Lyfgenia for sickle cell disease, which show potential despite challenging market conditions
Analyst Outlook
Price targets range from $2 to $40, reflecting diverse views on bluebird's future. Barclays maintains an Overweight rating, while RBC Capital Markets rates it Sector Perform
Strategic Restructuring
Learn how bluebird's cost-cutting measures aim to achieve cash flow break-even by H2 2025, balancing financial stability with the need for effective product launches
Read full SWOT analysis

Bluebird bio Inc Earnings Call Summary for Q3/2024

  • Patient starts more than doubled to 57 in Q3; Q4 revenue expected to rebound to $25M+ despite Q3 decline to $10.6M
  • Cash flow breakeven targeted for H2 2025, contingent on securing additional funding; 20% reduction in operating expenses planned
  • Over 50% of U.S. states confirm coverage for LYFGENIA; manufacturing capacity to double by 2026 to meet demand
  • Reverse stock split proposed to regain NASDAQ compliance; shareholder meeting scheduled for December 4
  • Company managing cash gap anticipated in Q2 2025 through contract renegotiations and partnerships
Last Updated: 2024-11-14, 03:58 p/m
Read Full Transcript

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-2.98 / -0.20
Revenue / Forecast
38.71M / 34.61M
EPS Revisions
Last 90 days

BLUE Income Statement

Compare BLUE to Peers and Sector

Metrics to compare
BLUE
Peers
Sector
Relationship
P/E Ratio
UnlockNaNNaNUnlock
PEG Ratio
UnlockNaNNaNUnlock
Price/Book
UnlockNaNNaNUnlock
Price / LTM Sales
UnlockNaNNaNUnlock
Upside (Analyst Target)
UnlockNaNNaNUnlock
Fair Value Upside
UnlockNaNNaNUnlock
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.